Similar articles for PMID: 12879280

Year	Number of Results
1977	1
1979	2
1982	1
1987	1
1989	1
1990	1
1992	1
1994	1
1997	1
1998	7
1999	6
2000	4
2001	3
2002	6
2003	23
2004	18
2005	14
2006	9
2007	9
2008	5
2009	4
2010	5
2012	2
2013	2
2014	1
2015	2
2016	1
2017	3
2018	3
2019	1
2020	2
2021	1
2024	0

1

Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.

Spieth K, Kaufmann R, Gille J. Spieth K, et al. Cancer Chemother Pharmacol. 2003 Nov;52(5):377-82. doi: 10.1007/s00280-003-0678-9. Epub 2003 Jul 22. Cancer Chemother Pharmacol. 2003. PMID: 12879280 Clinical Trial.

2

Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity.

Meden H, Wittkop Y, Kuhn W. Meden H, et al. Anticancer Res. 1997 May-Jun;17(3C):2221-3. Anticancer Res. 1997. PMID: 9216692 Clinical Trial.

3

Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.

Ehrich EW, Schnitzer TJ, McIlwain H, Levy R, Wolfe F, Weisman M, Zeng Q, Morrison B, Bolognese J, Seidenberg B, Gertz BJ. Ehrich EW, et al. J Rheumatol. 1999 Nov;26(11):2438-47. J Rheumatol. 1999. PMID: 10555907 Clinical Trial.

4

Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma.

Reichle A, Bross K, Vogt T, Bataille F, Wild P, Berand A, Krause SW, Andreesen R. Reichle A, et al. Cancer. 2004 Nov 15;101(10):2247-56. doi: 10.1002/cncr.20574. Cancer. 2004. PMID: 15470711 Free article.

5

Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).

Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter B, Lück HJ, Kimmig R, Pfisterer J. Meier W, et al. Gynecol Oncol. 2009 Aug;114(2):199-205. doi: 10.1016/j.ygyno.2009.04.026. Epub 2009 May 14. Gynecol Oncol. 2009. PMID: 19446314 Clinical Trial.

6

Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.

Ferrandina G, Ranelletti FO, Legge F, Lauriola L, Salutari V, Gessi M, Testa AC, Werner U, Navarra P, Tringali G, Battaglia A, Scambia G. Ferrandina G, et al. Clin Cancer Res. 2003 Oct 1;9(12):4324-31. Clin Cancer Res. 2003. PMID: 14555502 Clinical Trial.

7

[Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].

Wülfing C, Eltze E, Von Struensee D, Wülfing P, Bode ME, Bettendorf O, Piechota H, Hertle L. Wülfing C, et al. Aktuelle Urol. 2004 Aug;35(4):331-8. doi: 10.1055/s-2004-818537. Aktuelle Urol. 2004. PMID: 15459875 German.

8

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors.

Vogt T, Hafner C, Bross K, Bataille F, Jauch KW, Berand A, Landthaler M, Andreesen R, Reichle A. Vogt T, et al. Cancer. 2003 Nov 15;98(10):2251-6. doi: 10.1002/cncr.11775. Cancer. 2003. PMID: 14601096 Free article. Clinical Trial.

9

Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies.

Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM, Bornhäuser M, Ehninger G, Berdel WE, Baumgart J, Harstrick A, Bojko P, Wolf HH, Schindler AE, Seeber S. Scheulen ME, et al. Clin Cancer Res. 2000 Nov;6(11):4209-16. Clin Cancer Res. 2000. PMID: 11106234 Clinical Trial.

10

Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells.

Niederberger E, Manderscheid C, Grösch S, Schmidt H, Ehnert C, Geisslinger G. Niederberger E, et al. Biochem Pharmacol. 2004 Jul 15;68(2):341-50. doi: 10.1016/j.bcp.2004.03.029. Biochem Pharmacol. 2004. PMID: 15194006

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

133 results

Results by year